Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-607 in Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
NCT06117371Phase 1Completed
- Sponsor
- BeBetter Med
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of BEBT-607 in solid tumor (9 arms), sponsored by BeBetter Med. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose Limiting Toxicity at 4 weeks and 4 more. Started Sep 2023; status: completed.
02
Drugs
BEBT-607
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06117371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117371.